
CapsoVision, Inc. (CV)
$
5.59
-0.11 (-1.97%)
Key metrics
Financial statements
Free cash flow per share
-0.4114
Market cap
257.4 Million
Price to sales ratio
20.6301
Debt to equity
0.0478
Current ratio
5.1877
Income quality
0.8104
Average inventory
3.1 Million
ROE
0.6346
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Medical‑technology company developing advanced capsule endoscopy systems (CapsoCam Plus, CapsoCam Colon) and AI-enabled imaging platforms for gastrointestinal diagnostics
News

globenewswire.com
9 days ago
SARATOGA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, David Garcia, Senior Vice President of Finance, and Doug Atkinson, Senior Vice President of Global Sales, will participate in the Benchmark 14th Annual Discovery One-on-One Investor Conference on Thursday, December 4, 2025 in New York City.

globenewswire.com
a month ago
Conference Call Scheduled for Thursday, November 13, 2025 at 4:30 pm ET Conference Call Scheduled for Thursday, November 13, 2025 at 4:30 pm ET

globenewswire.com
4 months ago
- Conference Call Scheduled for Thursday, August 14, 2025 at 4:30 pm ET - SARATOGA, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced that the company will release second quarter 2025 financial results on Thursday, August 14, 2025, after the close of market.

globenewswire.com
5 months ago
SARATOGA, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced the closing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $5.00 per share. The shares began trading on the Nasdaq Capital Market on July 2, 2025 under the ticker symbol “CV.”

globenewswire.com
5 months ago
SARATOGA, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in its capsule endoscopy solutions, today announced the pricing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $5.00 per share. The shares are expected to begin trading on the Nasdaq Capital Market on July 2, 2025 under the ticker symbol “CV.” The offering is expected to close on July 3, 2025 subject to the satisfaction of customary closing conditions.

seekingalpha.com
5 months ago
Four IPOs and five SPACs debuted this week. Four IPOs and two SPACs submitted initial filings this week. The July IPO market is slated for a quiet start, with just a couple IPOs scheduled for the short Fourth of July week ahead.
See all news